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Background/Aims: Recently, increased body weight has 
been found to be associated with an increasing risk of sev-
eral cancers, including gastric cancer. The true pathogenic 
role of hyperglycemia in the development of gastric cancer 
remains unclear as hyperglycemia and its associated condi-
tions may work as carcinogenic factors. The goal of this study 
was to clarify the factors associated with early gastric cancer 
and evaluate a homeostasis model assessment of the in-
sulin resistance (HOMA-IR) index, fasting glucose, and lipid 
profile as predictors of early gastric cancer. Methods: A total 
of 63 patients with early gastric cancer between November 
2012 and March 2013 were included. Preoperative serum 
lipid profile levels and serum fasting glucose were examined 
prospectively in patients with early gastric cancer. The same 
number of controls were evaluated and matched to the early 
gastric cancer group for age and gender. We performed mul-
tivariate logistic regression analysis to identify independent 
risk factors for early gastric cancer. Results: Univariate analy-
sis showed that risk for early gastric cancer was associated 
with diastolic blood pressure (BP), total cholesterol, fasting 
glucose, and HOMA-IR. In the multivariate-adjusted model, 
higher total cholesterol, fasting glucose, body mass index, 
and diastolic BP were strongly associated with an increased 
risk of early gastric cancer. Conclusions: Hyperglycemia, a 
lower high-density lipoprotein cholesterol level, and a low 
HOMA-IR level appear to be associated with early gastric can-
cer risk. (Gut Liver 2019;13:154-160)
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INTRODUCTION
Gastric cancer is one of the most common causes of cancer 
induced deaths. Because of the survival of patients that have 
advanced gastric cancer is almost poor, early detection, and 
proper resection of the gastric malignant lesion at an earlier 
stage improves the survival.1-3 More effective approach for sur-
veillance of early gastric cancer (EGC) is needed. Various studies 
have improved that Helicobacter pylori infection is obvious risk 
factor for the carcinogenesis of stomach.4 However in addition 
to infection of H. pylori, multiple cofactors would play a role in 
gastric carcinogenesis. There were many evidences prove that 
patients of diabetes mellitus (DM) had a higher risk of cardio-
vascular disease and malignancies in various organs.5-8 Nev-
ertheless, few studies had focused on the relationship between 
DM, hyperglycemic state and the development of EGC.9 Authors 
have a question as to whether the development of EGC is related 
to insulin resistant state, not overt DM. 
Recently, there has been a study that adiponectin, one kind 
of adipokine, was elevated in advanced gastric cancer.10,11 The 
adiponectin is associated with the pathogenesis of DM through 
the regulation of glucose, metabolism of fatty acid, and insulin 
sensitivity in various epithelial and stromal cells.12,13 We mea-
sured it in a Korean population and examined the relationship 
between the development of EGC and plasma adiponectin lev-
els.
In this study, we evaluated insulin resistance (fasting glucose, 
fasting insulin, glycated hemoglobin [HbA1c], homeostasis 
model assessment of the insulin resistance [HOMA-IR], and 
HOMA β-cell function), lipid profile (total cholesterol [TC], high-
density lipoprotein [HDL], low-density lipoprotein [LDL], and tri-
glyceride [TG]) and plasma level of adiponectin in EGC patients 
and examined a possible role for adipokines in the development 
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of EGC.
MATERIALS AND METHODS 
1. Patients
This study is a case control prospective study performed 
in two centers (Kosin University Gospel Hospital and Yonsei 
Severance Hospital), from October 1, 2012 to March 31, 2013. 
We performed sample size assessment and determined that a 
total of 194 participants were needed, 97 in each group (EGC 
and controls). The inclusion criteria were aged between 18 to 
75 years old with written informed consent. The EGC group 
included patients who underwent endoscopic submucosal dis-
section or gastrectomy with conventional lymph node dissec-
tion and received pathological diagnosis of EGC. The control 
group was matched for age and sex (1:1) to the EGC group and 
subjects were enrolled from the health promotion center of each 
hospital. Subjects in both groups were excluded if they had any 
active malignancies (except gastric cancer for the EGC group) or 
a past history of any other malignancies. Exclusion criteria were 
patients with peptic ulcer disease or gastroesophageal reflux dis-
ease, oral hypoglycemic agents or insulin users due to diabetes, 
and patients taking oral lipid lowering agents due to hypercho-
lesterolemia. Study protocol was reviewed and approved by the 
Institutional Review Board (IRB No. KAIRB 13-152).
2. Assessment of study protocol
Clinical and pathological information of all subjects were ob-
tained from medical records. The body mass index (BMI) at the 
time of diagnosis was calculated based on weight (kg)/height 
(m)2. Subjects (EGC and control group) were provide informed 
consent prior to the collection and analysis of blood samples.
Serum was collected from all subjects after overnight or 12 
hours of fasting time. We requested that each subject be pro-
vided with a 10 mL blood sample at the time of admission or 
health checkup. The collected blood samples were stored at 
–80°C until analysis. 
Several parameters were measured that fasting glucose, 
HbA1c, and fasting insulin. We also investigated HOMA-IR and 
HOMA β-cell function as a value reflecting insulin resistance. 
The HOMA-IR score was calculated by the formula: (fasting in-
sulin [μU/mL]×fasting glucose [mmol/L])/22.5. HOMA-IR ≥1.96 
was defined as the presence of insulin resistance5 HOMA β-cell 
function was calculated by the formula: (20×fasting insulin [μU/
mL])/(fasting glucose [mmol]–3.5).5,14 Serum TC, TG, HDL and 
LDL values were determined by enzymatic methods. 
Plasma adiponectin levels were measured using an adipo-
nectin ELISA kit (Otsuka Pharmaceutical Co. Ltd., Tokushima, 
Japan). The adiponectin concentration was divided into two 
classes: The level of Adiponectin ≥8.0 ng/dL and <8.0 ng/dL.15 
H. pylori infection status was considered positive if the subjects 
had either H. pylori antibody ≥10 U/mL.15
3. Statistical analysis
For continuous variables, the results expressed as mean± 
standard deviation or median. The Student t-test and chi-square 
test were used to compare basic characteristics between the 
EGC and control groups. Matched odds ratios (ORs) and their 
corresponding 95% confidence intervals (CIs) were calculated 
using logistic regression models. p-values less than 0.05 were 
defined as statistically significant. All statistical analyses were 
performed with SPSS version 8.0 (SPSS Inc., Chicago, IL, USA).
222 Screening for eligibility
222 Informed consent
109 EGC group
13 Exclusion
Used oral hypoglycemic agent
Under lipid lowering agent
Other malignancy
Follow-up loss
96 EGC group
96 Control group
113 Control group
17 Exclusion
Used oral hypoglycemic agent
Under lipid lowering agent
Other malignancy
Comparison of fasting glucose level, HOMA-IR,
HOMA cell function, adiponectin level,
lipid profile level, infection

H. pylori
Fig. 1. Study flowchart. 
EGC, early gastric cancer; HOMA-
IR, homeostasis model assessment 
of the insulin resistance; H. pylori; 
Helicobacter pylori.
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RESULTS
From November 2012 to March 2013, we initially recruited 
a total of 222 participants. Among them, 13 participants in the 
EGC group were excluded because of use of oral hypoglycemic 
agents or lipid lowering agents or the presence of other malig-
nant disease. An additional 17 participants were excluded from 
the control group because of the presence of another malignant 
disease. We therefore included 96 individuals in the EGC group 
and control group, respectively, according to inclusion criteria. 
The study flow showed Fig. 1. Each group included 66 men 
and 30 women. Table 1 shows the basic characteristics of the 
two groups. There was no difference in height, weight, and BMI 
between the two groups, and the mean age was 55.6 years. The 
rate of H. pylori infection was higher in the EGC group than 
the control group. There were no statistically significant differ-
ences in the rate of alcohol consumption and smoking between 
groups. Fasting glucose, fasting insulin, HOMA-IR, HbA1c, TC, 
HDL, and diastolic blood pressure were statistically significant 
in the EGC group compared with control group. Although 
this difference was not statistically significant, serum level of 
adiponectin was lower in the EGC group (Table 1). The univari-
ate analyses showed that risk of cancer was slightly increased 
among persons with a higher level of fasting glucose, fasting 
insulin, HOMA-IR, HbA1c, and a lower level of TC and HDL. H. 
pylori infection was a significant risk factor in the EGC group 
(p=0.003). BMI, HOMA β-cell function, LDL, TG level, and 
adiponectin concentration were not associated with the risk 
of EGC development in this study (Table 2). The multivariate 
logistic regression analysis showed that high level of fasting 
glucose (OR=1.08, p<0.01), high level of fasting insulin (OR=1.69, 
p=0.02), HOMA-IR (OR=8.85, p=0.03), and lower level of TC 
(OR=1.01, p=0.005) were associated with the development of 
EGC (Table 3). HDL level was not affected in multivariate analy-
sis.
DISCUSSION
This is prospective, population-based study to report a posi-
tive association between insulin resistance and development of 
EGC in the absence of overt DM. This prospective study pro-
vided several salient findings. First, hyperglycemia (p=0.000, 
OR=1.066) and insulin resistance (fasting insulin [p=0.024, 
OR=1.084], HOMA-IR [p=0.006, OR=1.532] and HbA1C 
[p=0.004, OR=3.225]) were risk factors for the development of 
EGC. Second, a low level of TC (p=0.005, OR=1.015) was as-
sociated with the development of EGC. Third, although plasma 
adiponectin level was lower in EGC group, but there was no 
statistical significance. In a recent study, Ikeda et al.16 reported 
that hyperglycemia (fasting glucose ≥5.3 mmol/L) increased the 
risk of gastric cancer induced by H. pylori infection. Similar to 
their data, our prospective case control study demonstrated that 
the presence of hyperglycemia, hyperinsulinemia and elevated 
HOMA-IR were significantly related to the development of 
EGC based on multivariate analyses. A previous study showed 
that the incidence of gastric cancer is greater in patients with 
a higher level of HbA1C,17 and our data support this relation-
ship (p<0.01, OR=1.08). As the previous studies included AGC, 
it could not rule out secondary hyperglycemia as cancer prog-
ress. This study targeted EGC only excluding other variables, 
which makes higher possibility of EGC acting as main cause. 
There have been several studies dealing with relevancy between 
gastric dysplasia and hyperglycemia but this is the first time 
studying for EGC only. We also investigated plasma fasting 
insulin, calculated HOMA-IR and HOMA β-cell function that 
reflect insulin resistance.5,13 Among them, fasting insulin (p=0.02, 
OR=1.69) and HOMA-IR (p=0.03, OR=8.85) were confirmed to 
contribute to the development of EGC. 
Why does gastric cancer development occur more common in 
hyperglycemic state than in without hyperglycemia? The exact 
pathophysiological role of hyperglycemia in the development 
of stomach cancer remains to be unclear but several possible 
mechanisms have been suggested. The production of oxygen 
free radicals that cause DNA damage18 increases in hyperglyce-
mic state. High levels of glucose have been shown to contrib-
Table 1. Baseline Patient Characteristics of Early Gastric Cancer and 
Control Groups
Characteristic
EGC
(n=96)
Control
(n=96)
p-value
Age, yr 55.6±11.73 55.6±11.73 0.021
Sex, male/female 66/30 66/30
BMI, kg/m2 23.80±2.90 24.30±2.42 0.195
SBP, mm Hg 124.7±12.80 123.6±9.87 0.500
DBP, mm Hg 79.08±7.67 75.42±7.39 0.009
AC, cm 81.77±7.57 83.08±8.069 0.297
Total cholesterol, mg/dL 179.3±35.47 196.2±35.61 0.001
HDL, mg/dL 46.83±11.46 51.48±12.28 0.007
LDL, mg/dL 104.5±33.62 112.5±33.89 0.102
Triglyceride, mg/dL 129.8±71.84 139.7±136.5 0.529
TG/HDL index 3.09±2.17 3.26±5.39 0.773
Fasting glucose, mg/dL 98.61±15.89 87.41±13.30 0.001
Fasting insulin, mg/dL 6.27±7.09 4.33±3.16 0.015
HOMA-IR 1.56±1.71 0.96±0.75 0.002
HOMA β-cell 1.30±0.46 1.28±0.45 0.752
Adiponectin, ng/mL 8.28±4.98 8.61±6.23 0.685
HbA1C, % 5.82±0.47 5.63±0.38 0.002
Data are presented as mean±SD or number.
EGC, early gastric cancer; BMI, body mass index; SBP, systolic blood 
pressure; DBP, diastolic blood pressure; AC, abdominal circumfer-
ence; HDL, high-density lipoprotein; LDL, low-density lipoprotein; 
TG, triglyceride; HOMA-IR, homeostasis model assessment of the 
insulin resistance; HbA1C, glycated hemoglobin.
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ute to DNA damage in hyperglycemic patients.19 To the next, 
hyperinsulinemia itself is another possible mechanism of the 
development of gastric malignancy. Insulin is a key regulator 
of carcinogenesis in several organs including gastric cancer.20-23 
Table 2. Univariate Logistic Regression Analysis for the Risk of Early Gastric Cancer
Variable EGC (n=96) Controls (n=96) OR (95% CI) p-value
BMI, kg/cm2 0.931 (0.837–1.037) 0.1957
   <18.5  4 0
   18.5–25 66 60
   ≥25 26 36
FBS, mg/dL 1.066 (1.037–1.096) 0.0001
   <100 60 89
   ≥100 36  7
Fasting insulin, mg/dL 1.084 (1.011–1.162) 0.0243
   <6.20 70 73
   ≥6.20 26 23
HOMA-IR 1.532 (1.134–2.071) 0.0055
   <1.96 75 85
   ≥1.96 21 11
HOMA β-cell function 0.904 (0.485–1.685) 0.7508
   <1.18 67 69
   ≥1.18 29 27
HbA1C 3.225 (1.455–7.147) 0.0039
   <6.0 71 84
   ≥6.0 25 12
Adiponectin, ng/dL 0.99 (0.941–1.041) 0.6847
   <8.0 53 61
   ≥8.0 43 35
Total cholesterol, mg/dL 0.987 (0.978–0.995) 0.0018
   <200 68 60
   200–239 25 25
   ≥240  3 11
HDL, mg/dL 0.967 (0.943–0.992) 0.0089
   <40 30 17
   ≥40 63 79
LDL, mg/dL 0.993 (0.984–1.001) 0.1042
   <100 49 35
   100–129 26 37
   130–159 17 13
   ≥160  4 11
Triglyceride, mg/dL 0.999 (0.996–1.002) 0.5363
   <150 73 69
   ≥150 23 27
H. pylori infection - 0.003
   Positive 76 57
   Negative 20 39
EGC, early gastric cancer; OR, odds ratio; CI, confidence interval; BMI, body mass index; FBS, fasting blood sugar; HOMA-IR, homeostasis model 
assessment of the insulin resistance; HbA1C, glycated hemoglobin; HDL, high-density lipoprotein; LDL, low-density lipoprotein; H. pylori, Helico-
bacter pylori.
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Insulin may improve the bioavailability of insulin like growth 
factor 1 (IGF-1) by inhibiting the production of IGF-binding 
proteins.21,22 Bioavailable IGF-1 and insulin signal transduction 
develop pass through insulin, IGF-1, and hybrid receptors in 
the cell membrane.21,23 Inhibition of apoptosis, stimulation of 
cellular proliferation and carcinogenesis develop because of a 
number of downstream pathways activated by these receptors. 
Despite these possible mechanisms, further studies needed to 
clear the pathophysiological role of hyperglycemia and insulin 
resistance in gastric carcinogenesis. 
This study was able to more accurately survey the effects of 
insulin resistance in EGC by minimizing confounding factors 
such as BMI, AC, age, and sex. Identification of risk factors 
that precede the development of EGC can inform strategies to 
prevent EGC. Although several studies have evaluated the asso-
ciation between insulin resistance and gastric cancer, this study 
focused on EGC and possible associations with hyperglycemia 
and insulin resistance. In a recent study, it was found that there 
was inverse correlation between serum cholesterol levels and 
the incidence of gastric cancer, especially intestinal type.23,24 It 
is generally accepted that intestinal type cancer develops by 
a multistep leading to chronic active gastritis, gastric atrophy 
process and intestinal metaplasia from normal gastric mucosa 
and finally to dysplasia and cancer.25 These steps include the in-
flammatory process through activation of the pro-inflammatory 
transcription factor, nuclear factor κB (NF-κB).26 Cholesterol is 
an important structural lipid that required to maintain cell func-
tion.27 An experimental study showed that long term deficiency 
of serum cholesterol induces NF-κB activation, which could 
promote tumorigenesis.28 Accordingly, we investigated serum 
lipid profiles related to the development of EGC. Among serum 
lipid profiles, only TC (p=0.005, OR=0.985) was an independent 
risk factor in our study. In univariate analysis showed that HDL 
(p=0.009) was statistically significant factor, but not in multi-
variate analysis. Although cholesterol level is affected by dietary 
factors and several co-factors, the above mentions would some-
how support our results. 
Adiponectin is one of the active adipokines involved in the 
pathogenesis of diabetes through regulation of glucose and 
fatty acid metabolism and insulin sensitivity in various stro-
mal or epithelial cells.29-31 Excess adiposity, including visceral 
obesity, results in a state of chronic systemic low grade inflam-
matory state due to the production of inflammatory cytokines 
by both adipocytes and invasive immune cells, creating a pro-
tumorigenic environment.32 On the contrary, the circulating 
level of adiponectin is inversely correlated the risk of some 
cancers related to body mass index,29 and some polymorphisms 
of adiponectin and its receptor genes are correlated the risk of 
cancers.33 Many studies indicate that adiponectin has antican-
cer effects and plays an important role in the development and 
progression of obesity related malignant tumors.33-36 Ishikawa 
et al.37 recently reported that low plasma adiponectin concen-
trations are correlated an increased risk of gastric cancer and 
adiponectin is potentially involved in the progression of gastric 
cancer in especially in undifferentiated type cancers of the up-
per stomach. In a Nakajima et al.38 comparing 38 patients with 
Stage I gastric cancer and controls, adiponectin tended to de-
crease in cancer patients (p=0.0582), but the difference was not 
statistically significant. Based on these previous studies, we in-
vestigated the relationship of plasma adiponectin and the devel-
opment of EGC, excluding AGC. Plasma adiponectin tended to 
be lower in the EGC group (8.28±4.98 ng/mL) than in to control 
group (8.61±6.23 ng/mL), but the difference was not statistically 
significance. Plasma adiponectin could not be used as a conclu-
sive biomarker for the detection of EGC in our study. However, 
based on these recent studies low plasma adiponectin levels are 
correlated an increased risk for gastric cancer and it is likely 
that adiponectin may play a potential role in cancer progres-
sion,39-42 further larger scale, well-designed studies are needed to 
confirm this connection. 
This is the first study to examine the relationship of hypergly-
cemia, insulin resistance, lipid profile and adiponectin in EGC 
alone, excluding AGC. We revealed that elevated fasting glu-
cose and fasting insulin, HbA1c, HOMA-IR, and serum TC were 
independent risk factors of the development of EGC. Further-
more, general population with hyperglycemia or other elevated 
glycemic markers, should be advised to recommend appropriate 
gastric cancer screenings or surveillance even in the absence of 
obesity or diabetes. 
These are also limitations to this case-control study. First, 
the average glucose levels were within normal rage in both two 
group (98.61 vs 87.41). Although EGC group and Control group 
was not diagnosed overt DM and there was statistical signifi-
cance, it was not hyperglycemia, not even impaired glucose 
tolerance of impaired fasting glucose. Although interpretation 
of results may be a logical leap, but insulin resistance is time 
consuming and sequential events. As well as obesity and H. 
pylori infection, gastric carcinogenesis appear to be confounded 
by presence of shared cancer promoting or preventing factors. It 
Table 3. Multivariate Logistic Regression Analysis for the Risk of 
Early Gastric Cancer
Variable β SE p-value OR (95% CI)
DBP –0.920 0.030 0.002 0.912 (0.860–0.967)
Total cholesterol  0.015 0.005 0.005 1.015 (1.005–1.026)
HDL –0.018 0.016 0.263 0.982 (0.952–1.013)
Fasting glucose  0.084 0.024 0.001 1.088 (1.037–1.141)
Fasting insulin  0.525 0.233 0.025 1.690 (1.069–2.670)
HOMA-IR  2.181 1.019 0.032 8.853 (1.201–65.25)
HbA1C  0.721 0.514 0.160 2.057 (0.752–5.629)
SE, standard error; OR, odds ratio; CI, confidence intervals; DBP, 
diastolic blood pressure; HDL, high-density lipoprotein; HOMA-IR, 
homeostasis model assessment of the insulin resistance; HbA1C, gly-
cated hemoglobin.
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is difficult to accurate assessment of gastric cancer risk in sub-
jects because of these confounding factors. Thus, investigation 
into the substantial gastric cancer risk in participants requires 
adjustment based on these confounding factors. Therefore, well-
designed large scale prospective epidemiological studies are 
needed to confirm the association between diabetes and gastric 
carcinogenesis in humans. In conclusion, hyperglycemia and 
hyperinsulinemia in elevated insulin resistance may be related 
to the development of EGC. 
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